LUPUS NEPHRITIS

This study tests a drug called mosunetuzumab in 30 people with lupus, a disease where the immune system attacks the body. The goal is to see if the drug can put lupus into remission so that participants can stop most lupus medications for at least 6 months. However, some people m…

This phase 2 trial tests a one-time treatment called CC-97540, made from a patient's own immune cells engineered to target and calm the overactive immune system in lupus. The study enrolls 89 adults with active lupus (including kidney inflammation) who have not responded well to …

This study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see …

This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…

This study tests whether adding LUPKYNIS to standard biologic therapies (belimumab, obinutuzumab, or anifrolumab) can quickly improve kidney function in people with lupus nephritis. About 150 adults with biopsy-confirmed lupus kidney disease will receive the combination treatment…

This early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…

This study tests an experimental therapy called NKX019, which uses specially engineered immune cells from donors to target and calm overactive immune cells in people with lupus nephritis or primary membranous nephropathy. The trial involves 120 adults who have not responded to st…

This study tests whether adding the drug iptacopan to standard treatment helps people with active lupus nephritis (kidney inflammation caused by lupus) achieve better kidney function and fewer flares. About 240 adults with confirmed lupus nephritis will receive either iptacopan o…

This study tests a one-time treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with active lupus or lupus kidney disease that hasn't improved with standard therapies. About 179 adults will receive the treatment after a short chemotherapy …

This early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This study tests if obinutuzumab can help teens and children with lupus nephritis, a serious kidney complication of lupus. About 40 participants aged 5 to 17 will receive either the drug or a placebo. The goal is to see if the drug improves kidney function and reduces protein in …

This early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…

This early-phase trial is testing a new treatment for autoimmune disorders like lupus and scleroderma. It combines specially engineered natural killer cells (AD-PluReceptor) with a drug called tafasitamab and chemotherapy to try to control the disease. The study will enroll 47 pe…

This study tests a new treatment for adults with severe lupus that hasn't improved with standard therapies. Doctors will use a person's own immune cells, modified to target specific lupus-driving cells (CD19 or BCMA), and give them back as a one-time infusion. The goal is to cont…

This early-stage trial is testing a treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with lupus nephritis. CABA-201 is made from a patient's own immune cells, which are modified to target and temporarily remove B cells—a key dri…

This study compares two ways of dosing the drug mycophenolate mofetil (MMF) for children with lupus nephritis, a kidney disease caused by lupus. One method uses a standard dose based on body size, while the other adjusts the dose based on drug levels in the blood. The goal is to …

This 2-year extension study looks at lupus nephritis patients who finished a previous trial of ianalumab. Some patients who responded well will stop treatment to see if their kidney disease stays under control. Others who did not respond or were already on open-label ianalumab wi…

This study tests a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases. It is for people with severe, hard-to-treat conditions like lupus. The goal is to see if this therapy is safe and can control the…

This early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…

This early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (including lupus nephritis) that hasn't improved with standard treatments. The main goals are to check safety, find the best dose, and see early signs of effectiveness. Participants w…

This early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the dise…

This early-stage trial tests a new daily pill, IPG11406, in 36 adults with lupus nephritis—a kidney complication of lupus. The study checks if the drug is safe and whether it can reduce protein in the urine and improve kidney function. It is too soon to know if it works, but the …

This study tests an experimental drug called VIB4920 in people with active lupus nephritis, a serious kidney complication of lupus. About 74 adults will receive either VIB4920 or a placebo, along with standard medications, to see if the drug helps improve kidney function. The goa…

This Phase 3 trial tests whether a drug called obinutuzumab, combined with mycophenolate mofetil (MMF), can control lupus nephritis without the need for oral steroids. About 196 people with active lupus kidney disease will be randomly assigned to either the obinutuzumab/MMF regim…

This study tests whether combining two medications, belimumab and voclosporin, along with standard therapy, can help more people with lupus-related kidney disease achieve complete remission. About 30 adults with active lupus nephritis will take part. The goal is to see if this co…

This early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…

This study monitors the safety and effectiveness of the drug LUPKYNIS (voclosporin) in 400 adults with lupus nephritis under real-world conditions. Participants take LUPKYNIS alongside standard medications like steroids. The goal is to track side effects and see how well the drug…

This study follows 500 adults with lupus to see if blood and urine tests can reliably detect kidney inflammation (lupus nephritis). Participants give samples during routine visits, and doctors track their kidney health over time. The goal is to find simple, non-invasive markers t…

This study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…

This study follows up to 2000 people with immune-related kidney diseases, such as nephrotic syndrome and lupus nephritis. Researchers will collect medical history, lab tests, and blood or urine samples to better understand these conditions. The goal is to learn more about causes …

This study is building a large registry and biorepository of 3,500 adults with systemic lupus erythematosus (SLE), including those with lupus nephritis and neuropsychiatric lupus. Participants will provide clinical data and biospecimens over time, creating a resource for future r…

This study follows 300 adults with lupus nephritis who are already taking belimumab as part of their routine care. Researchers will track kidney function for up to 5 years to see how well the drug preserves renal health and prevents the need for dialysis or transplant. The goal i…

This study looks at whether doing a repeat kidney biopsy one year after starting treatment for lupus nephritis can help doctors decide if more treatment is needed. Half of the 206 participants will get the repeat biopsy, and the other half will follow standard care. The goal is t…